VC
CYTK icon

Vivo Capital’s Cytokinetics CYTK Stock Holding History

Vivo Capital’s Portfolio CYTK Stock Details CYTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-700,000
Closed -$13.9M – 61
2021
Q2 		$13.9M Hold
700,000
– – 0.6% 31
2021
Q1 		$16.3M Hold
700,000
– – 0.57% 34
2020
Q4 		$14.5M Hold
700,000
– – 0.65% 36
2020
Q3 		$15.2M Buy
+700,000
New +$16.4M 0.88% 32

Other funds holding CYTK

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
PAMS
Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Vivo Capital's CYTK Position: Q3 2021 in Review

Vivo Capital sold out of Cytokinetics (CYTK) in Q3 2021, closing a stake of 700,000 shares — an estimated $13.9M sold.

Vivo Capital first reported a position in CYTK in Q3 2020 and held it in 4 quarters. The position peaked at $16.3M in Q1 2021. 211 funds tracked by Wall St. Rank hold CYTK as of Q3 2021.

  • Vivo Capital reported no remaining Cytokinetics position as of Q3 2021 after selling out during the quarter.
  • Vivo Capital sold 700,000 Cytokinetics shares in Q3 2021, an estimated $13.9M.
  • Vivo Capital first reported a position in Cytokinetics in Q3 2020 and held it in 4 quarters.
  • Vivo Capital's Cytokinetics position peaked at $16.3M in Q1 2021.
  • 211 funds tracked by Wall St. Rank held Cytokinetics as of Q3 2021.

Based on Vivo Capital's 13F filing for Q3 2021, filed 15 Nov 2021.